Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionPoint72 Asset Management, L.P.
ManagerSteven Cohen
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Point72 Asset Management, L.P. ownership in DUL / Alnylam Pharmaceuticals, Inc.

On February 17, 2026 - Point72 Asset Management, L.P. filed a 13F-HR form disclosing ownership of 0 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $0 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 14, 2025 disclosing 6,197 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -100.00% during the quarter. The current value of the position is $0 USD.

Point72 Asset Management, L.P. has a history of taking positions in derivatives of the underlying security (DUL) in the form of stock options. The firm currently holds call options representing 5,600 of underlying shares valued at $1,852,872 USD and put options representing 700 of underlying shares valued at $231,609 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:DUL / Alnylam Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-02-17 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -6,197 -100.00 0 -100.00
2025-11-14 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,197 -195,199 -96.92 2,826 -95.70 0.0047
2025-08-14 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 201,396 -99,239 -33.01 65,673 -19.10 0.1289
2025-07-21 2025-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 300,635 300,635 81,178 0.1853
2025-05-15 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 300,635 300,635 81,178 0.1853
2024-09-16 2024-06-30 13F/A-2 ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -206,255 -100.00 0 -100.00
2024-08-19 2024-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 0 0
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 0
2024-05-15 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 206,255 120,265 139.86 30,825 87.28 0.0747
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 85,990 85,990 16,459 0.0398
2023-05-15 2022-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -14,570 -100.00 0 -100.00
2023-02-14 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -14,570 0
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,570 -318,630 -95.63 2,916 -94.00 0.0116
2022-08-15 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 333,200 333,200 48,597 0.2050
2022-02-14 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -99,512 -100.00 0 -100.00
2021-11-15 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 99,512 -20,177 -16.86 18,789 -7.40 0.0825
2021-08-16 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 119,689 -320,248 -72.79 20,290 -67.33 0.0912
2021-05-17 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 439,937 -41,963 -8.71 62,115 -0.83 0.2902
2021-02-16 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 481,900 481,900 62,633 0.3055
2019-11-15 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -398,928 -100.00 0 -100.00
2019-08-14 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 398,928 398,928 28,946 0.1514
2019-02-14 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -885,312 -100.00 0 -100.00
2018-11-14 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 885,312 -471,096 -34.73 77,483 -42.00 0.3195
2018-08-14 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,356,408 448,362 49.38 133,593 23.53 0.5332
2018-05-15 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 908,046 819,160 921.58 108,148 857.66 0.4521
2018-02-14 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 88,886 3,886 4.57 11,293 13.08 0.0487
2017-11-14 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 85,000 35,000 70.00 9,987 150.43 0.0446
2017-08-14 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 50,000 50,000 3,988 0.0224
2015-02-17 2014-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -12,100 -100.00 0 -100.00
2014-11-14 2014-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,100 12,100 945 0.0071
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM Call 5,600 -12.50 1,853 -27.20 n/a n/a n/a
2026-02-17 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM Call 6,400 2,545 n/a n/a n/a
2018-02-14 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2017-11-14 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM Call 100,000 11,749 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM Put 700 -85.11 232 -87.63 n/a n/a n/a
2026-02-17 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM Put 4,700 -79.11 1,869 -81.79 n/a n/a n/a
2025-11-14 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM Put 22,500 10,260 n/a n/a n/a
2018-02-14 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2017-11-14 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM Put 150,000 17,624 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.